Recent Updates
Recently added Catalysts

Trivalent influenza vaccine GSK 138842A

Phase 1

Influenza | Monoclonal antibody | Infectious Disease |GSK plc|Last Updated: Jun 8, 2018

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment200
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00693706Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 1388442A Compared With FluarixPHASE1 COMPLETED 200Jun 2, 2008Mar 26, 2009Jun 8, 20182 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Subjects With Solicited Local Symptoms.
During the 7-day (Days 0-6) post vaccination period

Solicited local symptoms were pain, redness and swelling at the injection site. Any = occurrence of a symptom regardless of intensity.

Number of Subjects With Solicited General Symptoms.
During the 7-day (Days 0-6) post vaccination period

Solicited general symptoms were arthralgia, fatigue, headache, muscle aches, shivering and temperature, assessed as oral temperature above or equal (≥) 38.0 degrees Celsius (°C). Any = occurrence of a symptom regardless of intensity or relationship to vaccination.

Number of Subjects With Medically Attended Adverse Events (MAEs).
During the entire study period (Days 0-182)

Medically-attended events (MAEs) refer to non-serious and serious events leading to an otherwise unscheduled visit to or from medical personnel for any reason, including emergency room visits and hospitalization. Related MAE = MAE assessed by the investigator as related to the vaccination.

Number of Subjects With New Onset of Chronic Diseases (NOCDs).
During the entire study period (Days 0-182)

NOCDs include conditions such as autoimmune disorders, asthma, type I diabetes, or allergies.

Number of Subjects With Unsolicited Adverse Events (AEs).
During the 90-day (Days 0-89) post-vaccination period

Unsolicited AEs cover any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any unsolicited AE = any unsolicited AE regardless of intensity or relationship to vaccination.

Number of Subjects With Serious Adverse Events (SAEs).
During the entire study period (Days 0-182)

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any SAE = any SAE regardless of intensity or relationship to vaccination.

Titers for Serum Hemagglutination Inhibition (HI) Antibodies for 3 Strains of Influenza Disease.
At Day 21

Titers are presented as geometric mean titers (GMTs). The 3 influenza strains assessed were A/Solomon Islands/3/2006 (H1N1), A/Wisconsin/67/2005 (H3N2) and B/Malaysia/2506/2004 (MALAY.)

Number of Seroprotected Subjects Against 3 Strains of Influenza Disease.
At Day 21

A seroprotected subject was defined as a vaccinated subject with a serum HI antibody titer ≥ 1:40, a level of HI antibody that has been viewed as correlating with protection against influenza. The 3 influenza strains assessed were A/Solomon Islands/3/2006 (H1N1), A/Wisconsin/67/2005 (H3N2) and B/Malaysia/2506/2004 (MALAY.)

Number of Seroconverted Subjects Against 3 Strains of Influenza Disease.
At Day 21

A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer \<1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 3 influenza strains assessed were A/Solomon Islands/3/2006 (H1N1), A/Wisconsin/67/2005 (H3N2) and B/Malaysia/2506/2004 (MALAY.)

Geometric Mean Fold-rise (GMFR) in 3 Strains of Influenza Disease.
At Day 0 and Day 21

GMFR was defined as the geometric mean of the ratio of the post-vaccination inverse HI titer to the Day 0 inverse HI titer. The 3 influenza strains assessed were A/Solomon Islands/3/2006 (H1N1), A/Wisconsin/67/2005 (H3N2) and B/Malaysia/2506/2004 (MALAY.)

Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
GSK 1388442A GroupEXPERIMENTALSubjects aged 18 to 49 years of age at the time of vaccination received 1 dose of GSK 1388442A vaccine at Day 0. The GSK 1388442A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
Fluarix GroupACTIVE_COMPARATORSubjects aged 18 to 49 years of age at the time of vaccination received 1 dose of Fluarix® vaccine at Day 0. The Fluarix® vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
Interventions
NameTypeDescription
Trivalent influenza vaccine GSK 138842ABIOLOGICALIM injection on Day 0
FluarixBIOLOGICALIM injection on Day 0
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 49 Years
SexALL
Healthy VolunteersYes
Study Sites2

Inclusion Criteria: * Subjects who the investigator believes can and will comply with the requirements of the protocol * A male or non-pregnant, non-lactating female between 18 and 49 years of age at the time of vaccination * Access to a telephone for scheduled follow-up telephone contacts * Abilit...

Countries:United States
Unlock Eligibility Criteria